SV

Street Verdict

Analyst Scorecard

APLLTD · NSE

Alembic Pharmaceuticals Limited

₹845.75

+2.39% (+₹19.75)

Prev. close

₹826

Volume

6,34,938

Delivery %

43.7%

As of

18 Sept 2026

Price history

₹845.75+₹108.55 (+14.72%) · 3M
10 Jun 2026 → 18 Sept 2026
₹850.05₹734.6510 Jun03 Jul03 Aug26 Aug18 Sept
Daily closes · updates after each session

No analyst calls on this stock in the last 90 days yet.

Explore by date range →

Analyst opinions

No analyst calls on Alembic Pharmaceuticals Limited in the last 90 days.

Fundamentals

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Chirayu Ramanbhai Amin

Headquarters

Vadodara

Employees

17,244

Key stats

Market cap

₹16,624.33 Cr

P/E ratio (TTM)

24.0

Dividend yield

1.45%

EPS (TTM)

₹35.27

Beta (1Y · daily vs NIFTY 50)

0.90

Beta (5Y · monthly vs NIFTY 50)

1.10

Shares float

5.76 Cr

EPS · quarter ended Jun 2026

₹8.80

Financial Performance

01 · Financials

0 Cr2500 Cr5000 Cr7500 Cr₹-10%0%10%20%FY21FY22FY23FY24FY25FY26
RevenueEBITDARevenue growth YoY

FY21 growth needs FY20 filings, which the data source doesn't provide. Net income is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.

02 · Earnings Per Share (EPS)

0255075₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

051015₹-100%-50%0%50%16 Mar 2019 Jul 2117 Aug 2228 Jul 2315 Jul 2429 Jul 2529 Jul 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-100%0%100%200%FY21FY22FY23FY24FY25FY26
SalesFixed assetsReceivables (trade + unbilled)Inventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr2500 Cr5000 Cr7500 Cr10000 Cr₹0×0.25×0.5×0.75×1×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr2500 Cr5000 Cr7500 Cr10000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-1000 Cr0 Cr1000 Cr2000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹5,393.13 Cr₹5,305.79 Cr₹5,652.62 Cr₹6,228.63 Cr₹6,672.08 Cr₹7,344.90 Cr
EBITDA₹1,567.58 Cr₹924.62 Cr₹680.19 Cr₹961.66 Cr₹1,064.53 Cr₹1,105.89 Cr
—₹545.68 Cr₹341.99 Cr₹615.82 Cr₹583.42 Cr₹674.77 Cr
Diluted EPS₹60.81₹27.76₹17.4₹31.33₹29.68₹34.33

Net income has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹6,708.98 Cr₹7,122.03 Cr₹6,183.00 Cr₹6,446.00 Cr₹7,773.00 Cr₹8,763.00 Cr
₹583.61 Cr₹717.11 Cr₹722.01 Cr₹513.16 Cr₹1,257.50 Cr₹1,429.94 Cr
Stockholders' equity₹5,066.97 Cr₹5,237.55 Cr₹4,370.00 Cr₹4,818.00 Cr₹5,191.00 Cr₹5,675.00 Cr

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,463.38 Cr₹552.30 Cr₹724.00 Cr₹803.00 Cr₹88.00 Cr₹783.00 Cr
Investing cash flow₹-838.81 Cr₹-371.97 Cr₹-447.60 Cr₹-320.61 Cr₹-568.41 Cr₹-506.05 Cr
₹-597.43 Cr₹-217.30 Cr₹-262.00 Cr₹-438.00 Cr₹444.00 Cr₹-164.00 Cr
Capital expenditure₹-659.51 Cr₹-425.64 Cr₹-443.00 Cr₹-327.00 Cr₹-564.00 Cr₹-495.00 Cr
End cash position₹98.06 Cr₹61.09 Cr₹75.48 Cr₹120.21 Cr₹83.48 Cr₹196.37 Cr

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21–Dec 21(2Q)Mar 22–Dec 24(12Q)Mar 25–Jun 25(2Q)Sep 25–Mar 26(3Q)Jun 26
Promoter69.48%69.61%69.67%69.74%69.87%
Public30.52%30.39%30.33%30.26%30.13%
Employee trusts0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.48 L Cr₹1,837.337.05.3613.7%0.06+11.9%+11.4%
Divi's Laboratories Limited₹2.47 L Cr₹9,37583.314.7715.3%0.00+12.3%+53.4%
Torrent Pharmaceuticals Limited₹1.83 L Cr₹4,87576.921.8225.8%1.79+21.5%+37.4%
Apollo Hospitals Enterprise Limited₹1.26 L Cr₹8,944.560.413.3020.5%0.90+15.7%+13.9%
Lenskart Solutions Limited₹1.18 L Cr₹707.2179.913.485.6%0.35+35.4%—
Zydus Lifesciences Limited₹1.13 L Cr₹1,16025.34.1818.6%0.46+18.4%+10.7%
Cipla Limited₹1.10 L Cr₹1,376.332.53.1911.3%0.02+2.1%-11.8%
Laurus Labs Limited₹1.05 L Cr₹1,95496.419.8616.8%0.48+22.0%+111.6%
Max Healthcare Institute Limited₹1.01 L Cr₹1,049.369.89.3913.4%0.32+19.0%-10.6%
Dr. Reddy's Laboratories Limited₹97,876.16 Cr₹1,18529.62.6011.4%0.21+3.2%-10.4%
Manipal Health Enterprises Limited₹97,364.22 Cr₹738.95146.611.567.8%1.53+18.0%—
Alembic Pharmaceuticals Limited₹15,862.64 Cr₹810.9522.92.8011.9%0.25+10.3%-16.4%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Annual reports

Show all 16

Concall transcripts

Show all 11

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

Index membership

10 indices

BSE Healthcare· 0.3%Nifty Smallcap 500· 0.1%Nifty Total Market· 0.0%BSE 1000· 0.0%BSE 1000 MULTICAP EQUAL SIZE WEIGHTED (25%)BSE 250 MICROCAPBSE NEXT 500BSE Smallcap 500BSE Total MarketNifty Microcap 250

NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.

APLLTD

Alembic Pharmaceuticals Sets Up Wholly Owned Subsidiary in Dubai to Drive Global Expansion

TipRanks · 11 days ago